Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Valproic acid (VPA) has been demonstrated to be able to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in inducing the differentiation of acute myeloid leukemia (AML) cells. A pilot study of the VPA/ATRA combination was performed in 11 elderly patients with de novo AML (median age, 82 years). Complete marrow response was observed in 3 patients, including 1 complete remission. Two additional patients had hematologic improvement.
Emmanuel
E
Raffoux
Pascal
P
Chaibi
Hervé
H
Dombret
Laurent
L
Degos
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D010865:Pilot Projects; D013997:Time Factors; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage*; D014635:Valproic Acid / Q000008:administration & dosage*
D014212:Tretinoin; D014635:Valproic Acid